UAE has approved the emergency use of Sinopharm CNBG’s new recombinant protein vaccine. This comes following strict monitoring and evaluation of data from a study conducted in the UAE.
The study included individuals who were previously vaccinated with two doses of Sinopharm CNBG’s inactivated vaccine. The seroconversion rate (efficacy) was up to 100 per cent in producing neutralising antibodies. No side effects were recorded among any of the participants.
The vaccine demonstrated an improved immune capacity against SARS-CoV-2 variants, with a high safety rate that allows rapid production and easy storage and distribution.
The UAE-based study has also shown an immune response against new variants of the virus in volunteers.
